Purpose: To describe clinical features, risk factors and complications in a cohort of Swedish children with juvenile idiopathic arthritis (JIA) screened for uveitis between 2002 and 2011. Methods: Medical records of 299 children with JIA (93 male, 206 female; median age 5.0 years at diagnosis) were retrospectively scrutinized focusing on subtype of JIA, onset of arthritis/uveitis, presence of antinuclear antibodies (ANA) and ophthalmological status. Results: Uveitis was found in 32 (11%) children, 78% bilaterally affected. The median age of arthritis onset in children who developed uveitis was 2.5 years (range 1-10) versus 5.0 years (range 1-15) in those who did not. Sex ratio was 3.5:1 (girl: boy). The most prevalent JIA subtype was oligoarthritis (75%). All but one child with uveitis was found to be ANA (+). The median interval between diagnosis of arthritis and uveitis was 12 months. Only one child developed uveitis between the fourth and fifth years after arthritis onset. Ocular complications were recorded in 45.6% (26/57 affected eyes) at last follow-up. On univariate analysis, both young age at arthritis onset and ANA positivity were possible predictors for developing uveitis, but on multivariate analysis, the latter was the most important predictor (HR 16.25, 95%;; p = 0.006, Cox regression analysis). Conclusion: Almost all of the children developing JIA-associated uveitis did so within 4 years after arthritis onset, a fact that accentuates the importance of early initiation of ophthalmological screening and more frequent regular follow-ups during the first 4 years. The most important predictor for developing uveitis was ANA positivity.
Introduction
Juvenile idiopathic arthritis (JIA) is an inflammatory disorder characterized by chronic arthritis. It is a clinical diagnosis in children younger than 16 years of age with arthritis defined as swelling or limitation of motion of the joints accompanied by heat, pain or tenderness for at least six-week duration with no other identifiable causes of arthritis. Juvenile idiopathic arthritis (JIA) has been classified by the International League of Associations for Rheumatology (ILAR) into seven subtypes including systemic, oligoarthritis (OA), polyarthritis (PA) rheumatoid factor (RF) positive and RF negative, enthesitis-related arthritis (ERA), psoriatic and 'other' JIA (Petty et al. 1998 ). The classification system was developed to identify clinically homogenous JIA subtypes to facilitate communication regarding epidemiology, therapeutics and outcomes globally (Weiss & Ilowite 2005) . Juvenile idiopathic arthritis is the most common rheumatic illness in children in the Western world (Thierry et al. 2014) . According to the literature, OA (50-60%), PA (30-35%), systemic (10-20%) and ERA (1-7%) are the most common JIA subtypes (Weiss & Ilowite 2005) .
Juvenile idiopathic arthritis (JIA) might lead to several complications such as deformity of joints, growth disturbances and osteoporosis. The most insidious and devastating complication is uveitis (anterior uveitis/iritis), which is the most common extra-articular manifestation of JIA (Saurenmann et al. 2010) . This type of intraocular inflammation is usually asymptomatic, associated with increased ocular morbidity (Saurenmann et al. 2010 ) and might occur before, simultaneously or after the onset of arthritis (Asproudis et al. 2010 ). Chronic uveitis can cause complications including cataract, secondary glaucoma, band keratopathy, posterior synechiae, hypotony and macular oedema. This ocular morbidity associated with JIA-uveitis may be continued in adulthood (Skarin et al. 2009) . A retrospective study from the Netherlands showed that there were significantly more complications in acquired and non-infectious childhood uveitis, for example JIA-associated uveitis compared with congenital and infectious uveitis (Hettinga et al. 2014) .
Because of the absence of initial signs and symptoms, it is important that paediatric rheumatologists refer all children recently diagnosed with JIA to an ophthalmologist for examination and to maintain periodical follow-up visits based on JIA subtype and onset of arthritis. Screening guidelines for early detection of uveitis in JIA vary across countries and are based on the perception of risk of intraocular inflammation.
There is a paucity of data on epidemiology of children with JIA-associated uveitis from Scandinavian countries, especially in Sweden. The purpose of the present research was to study a cohort of children with JIA that have been screened for uveitis at The Queen Silvia Children's hospital in Gothenburg, Sweden, between 2002 and 2011 and to assess the outcome of the ophthalmological screening with regard to clinical features, risk factors and complications in children developing uveitis in order to find possible predictors for uveitis in this JIA population.
Materials and Methods
We conducted a retrospective study identifying 299 children diagnosed with JIA that had been screened for uveitis at The Queen Silvia Children's hospital, which belongs to the Sahlgrenska University Hospital in Gothenburg, Sweden, over a 10-year period from 2002 to 2011. All subjects included in the study were under the age of 18, this being the cut-off age for paediatric patients in Sweden. Patients who had signs and symptoms of other arthritis such as para-/post-infectious arthritis, connective tissue disorder, systemic vasculitis, malignancy or metabolic diseases were excluded. The diagnosis of JIA and identification of subtypes of JIA were based on the ILAR 2004 revised criteria (Petty et al. 2004) . Patients whose diagnoses were made prior to the use of the ILAR criteria were subsequently diagnosed retrospectively by the paediatric rheumatologist (S.O) as having JIA according to the ILAR criteria. Screening had been performed at fixed intervals based on screening guidelines for uveitis in JIA provided by the British Society for Paediatric and Adolescent Rheumatology (BSPAR) (http://www.bspar.org. uk/clinical-guidelines). First screening had been performed within 2 to 4 weeks of referral, and all children had been screened until 12 years of age. For children with ANA-positive oligoarthritis with onset of arthritis under 4 years, three-monthly interval had been performed for 5 years, thereafter six-monthly interval. All other subtypes of JIA, except for systemic JIA, with arthritis onset under 7 years had been screened every 3 months for 2 years, thereafter every 6 months. Oligoarthritis, ANA-positive polyarthritis and psoriatic arthritis with onset between 7 and 12 years had been screened every 6 months. Children with systemic, enthesitis-related and ANA-negative polyarthritis JIA with onset of arthritis between 7 and 12 years had been screened every 6 months for 1 year, thereafter once a year. Adolescents with all subtypes of JIA with onset of arthritis between 12 and 16 years had not been screened but examined once and informed of iritis symptoms.
Data on initial and subsequent screening intervals were registered. The paediatric rheumatological database included age, gender, arthritis subtype and age at onset of arthritis. The presence of antinuclear antibodies (ANA) was documented. The following ophthalmological variables were registered: age at onset of uveitis, presence of uni-or bilateral uveitis and ocular complications such as cataract, secondary glaucoma (inflammatory/steroid-induced), ocular hypertension, posterior synechiae, band keratopathy, vitritis, macular oedema, papilloedema, hypotony and blindness. Glaucoma was defined as elevated intraocular pressure (IOP) (>21 mmHg) in the presence of irreversible optic nerve damage and progressive visual field loss. Ocular hypertension was defined as elevated IOP (>21 mmHg) in the absence of optic nerve damage or visual field loss. Children with uveitis were grouped into two categories: those who developed severe and those who developed mild uveitis. Severe uveitis was defined as the presence of one or more ocular complications such as posterior synechiae, band keratopathy, cataract, secondary glaucoma, ocular hypertension treated with antiglaucoma agents, vitritis and macular oedema as detected at any of the follow-up examinations.
Complications that needed surgery and the type of surgical procedure were recorded. Furthermore, second-line systemic immunosuppressive treatment such as methotrexate and biological agents received by all JIA children, and type of local treatment in children with uveitis, were also documented during follow-up.
Statistical analysis
Statistical analyses were conducted using SAS software, Version 9.4 (SAS Institute Inc, Cary, NC, USA). Descriptive statistics (means, standard deviations (SD), medians and range) were used to summarize the data. For categorical variables, frequencies and percentages were reported. For comparison between groups, Fisher's exact test was used for dichotomous variables and the Mann-Whitney U-test was used for continuous variables. Differences between groups were considered significant if the p-value was <0.05. Cox regression analysis (univariate and multivariate analysis) was used to identify risk factors for development of uveitis.
Ethical approval
The study was approved by the Ethical Committee at the Medical Faculty, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, and conducted according to the Declaration of Helsinki.
Results
A total of 299 children with JIA who were screened for uveitis at the Department of Paediatric Ophthalmology, The Queen Silvia Children's Hospital, Gothenburg, Sweden, over a period of 10 years (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) were identified. Table 1 shows all 299 children with JIA categorized by subtype as defined by the ILAR criteria, with OA being most prevalent subtype (57.5%). Of the 299 children, 206 (68.9%) were girls, with a female-to-male ratio of 2.2:1. All but one of the children were Caucasian (one Asian).
Uveitis was found in 32 children (10.7%) and was detected for the first time at a median age of 5.0 years (range 2-10 years). The characteristics of children with JIA and JIA-associated uveitis are shown in Table 2 . Children with uveitis were significantly younger at onset of arthritis, and more often ANA positive, with OA and undergoing second-line treatment than children with JIA without uveitis ( Table 2) . Bilateral uveitis was found in 25 children (78.1%). Among the 32 children with uveitis, 78.1 per cent (n = 25) were girls, with a female-to-male ratio of 3.5:1. The sex ratio in children without uveitis was 2:1 (181 girls and 86 boys). The distribution of ANA positivity was significantly different between children with uveitis (31 of 32, 96.9%) and without uveitis (132 of 251, 52.6%, data missing for 16 children; p = <0.0001, Fisher's exact test, see Table 2 ).
The median age of arthritis onset in children who developed uveitis was 2.5 years (range 1-10 years), whereas in children without uveitis, the median age was 5 years (range 1-15 years), (p = 0.0001, Mann-Whitney U-test). The median time interval between the diagnosis of arthritis and the diagnosis of uveitis was 12 months (range: 7 months prior to-72 months after diagnosis). In one girl, uveitis was diagnosed 7 months before the onset of arthritis. Of all 32 children, only one developed uveitis between the fourth and fifth years after arthritis onset.
On univariate analysis (Cox regression analysis), ANA positivity and young age at onset of arthritis were potential predictors of uveitis development (Table 3) . On multivariate analysis, ANA positivity remained significant and thus the most important predictor of uveitis (HR 16.25, 95%; , Cox regression analysis).
Fifteen (46.8%) of the children with uveitis (26 of 57 affected eyes, 45.6%) developed ocular complications as shown in Table 4 (Figs 1 and 2 ). The only complication that was documented at first visit was the formation of posterior synechiae in eight eyes (14%) of six children (19%). The distribution of gender, ANA positivity, different JIA subtypes, age at onset of arthritis and uveitis, second-line treatment, time interval between arthritis and uveitis did not differ significantly between children with severe (13/32; 40.6%) and mild uveitis (19/32; 59.4%). Severe uveitis developed in five children with persistent OA (5/13), four children with extended OA (4/13) and four with RF-negative PA (4/13).
Cataract extraction with implantation of intraocular lens (IOL) combined with pars plana vitrectomy (PPV) as previously described (P alsson et al. 2015) was the most frequent surgical procedure, performed in eight eyes (14%), followed by glaucoma drainage device surgery (Molteno drainage implant) performed in six eyes (10%).
Twenty-six (81.3%) of the children with uveitis compared to 153 (57.3%) of those without uveitis were on second-line systemic immunosuppressive treatment. Methotrexate was the most frequently used agent (179/299; 59.8%). Other drugs used include etanercept, adalimumab, infliximab, sulphasalazine, hydroxychloroquine, azathioprine, cyclosporine and cyclophosphamide. Concerning the children with uveitis, 18/32 (56.2%) had no second-line systemic treatment, 13 (40.6%) were on methotrexate and one child (3.1%) on hydroxychloroquine at uveitis onset. At last follow-up examination, only seven children (21.8%) had no systemic secondline treatment, 10 children (31.2%) were on methotrexate as monotherapy, 14 (43.7%) were on both methotrexate Table 1 . Distribution of juvenile idiopathic arthritis (JIA) subtypes among all children diagnosed with JIA (n = 299) divided into children with uveitis (n = 32) and without uveitis (n = 267).
JIA subtype
Children with JIA, n = 299 n (%) Children without uveitis, n = 267 n (%) Children with uveitis, n = 32 n (%) p-value and one of the TNF-a inhibitors and one child (3.1%) had adalimumab as monotherapy (Table 5 ). All children with uveitis were treated with topical steroids. Topical antiglaucoma agents were used in 13 children with ocular hypertension and glaucoma.
Discussion
JIA-associated uveitis is a chronic, silent intraocular inflammation which may lead to significant visual loss due to several serious complications. It is one of the leading causes of preventable blindness in the world and the most common and most significant extra-articular manifestation of JIA (Saurenmann et al. 2010) . In the present study of about 300 children with JIA, uveitis was noted in almost 11%. This incidence does probably not reflect the total number of uveitis cases in this cohort study concerning the fact that some cases of JIA-associated uveitis may occur over the age of 18 years (Skarin et al. 2009 ), which is the upper limit of the group studied.
For those who developed uveitis, OA was the most prevalent JIA subtype (75%), a majority were girls (78%) and almost all were ANA positive (97%).
The most important predictor for developing uveitis was ANA positivity. Most of the epidemiological characteristics found in our study are in accordance with previous studies in Caucasian children (Kotaniemi et al. 2001; Heiligenhaus et al. 2007 ). In a multicentre study conducted in Germany in 2007, in which 3271 patients with JIA from 35 centres were analysed, it was found that 406 children (12%) had uveitis, and the vast majority (79%) had OA, started early and were predominantly girls (74%) with positive ANA (86%) (Heiligenhaus et al. 2007) . In this study, the mean age of arthritis onset in children who developed uveitis was 3.4 years and the mean time interval between the diagnosis of arthritis and the diagnosis of uveitis was 17 months, which is in accordance with the results (3.8 years and 21 months, respectively) presented by Heiligenhaus et al. 2007 . According to Heiligenhaus, it appears that approximately 75% of children with arthritis will have developed uveitis by their seventh birthday and the risk decreases after 7 years of disease (Paroli et al. 2003; Sim et al. 2006; Heiligenhaus et al. 2007 ).
According to other authors, 75% of children who developed uveitis did so within approximately 3 years of their JIA diagnosis (Saurenmann et al. 2007a; Woreta et al. 2007 ) and 90% developed uveitis within the first 4 years of arthritis diagnosis (Kotaniemi et al. 2001; Heiligenhaus et al. 2007) . A recent cohort study conducted in the USA (Angeles-Han et al. 2015) showed that cumulatively, 86% of children were diagnosed with uveitis within 4 years of their JIA diagnosis and 94% within 5 years. In our study, all but one child (97%) developed uveitis within the first 4 years after arthritis onset. The present study confirms known risk factors associated Fig. 1 . Macular oedema was developed eight to 9 months after discontinuing treatment with adalimumab (40 mg sc/week) due to the serious adverse event of intracranial and orbital abscess. Besides treatment with methotrexate, and oral steroids, as the macular oedema was refractory, the boy received a dexamethasone intravitreal implant (OzurdexÒ). The macular oedema resolved, but the boy has poor vision (VA 20/400, logMAR ≥1.30) in the right eye due to a cataract.
with the development of uveitis in children with JIA, such as ANA positivity, young age at JIA diagnosis and OA subtype. As determined by multivariate analysis, ANA positivity was the most significant predictor in our study, whereas Angeles-Han and coworkers demonstrated that only the OA subtype and young age at arthritis diagnosis were significant predictors using multivariate analysis (AngelesHan et al. 2015) . In general, uveitis is thought to be more common in the OA subtypes, particularly in the extended OA subtype (Kotaniemi et al. 2001; Sim et al. 2006) . Sim et al. (2006) noted that children with extended OA had the highest prevalence of uveitis (25%) and they developed uveitis earlier than the persistent group. In our study, persistent OA had the highest prevalence (50%) but neither extended nor persistent OA were significant predictors for the development of uveitis.
In a study from the USA of 89 children (165 eyes) with JIA-associated uveitis, 64% of the affected eyes developed cataracts, 58% posterior synechiae, 46% band keratopathy, 26% maculopathy and 20% glaucoma (Kump et al. 2006) . These high percentages of ocular complications may be due to the referral to a tertiary eye centre where the study was conducted. A study from Finland revealed that complications had developed in 25 of 104 children (24%) with uveitis, of which cataracts were the most common (22%) (Kotaniemi et al. 2001 ). The results from these studies and the present study are summarized in Table 6 .
Several risk factors have been associated with vision loss and ocular complications in JIA-associated uveitis, such as severe disease and complications at initial ophthalmology examination, presence of uveitis before arthritis, short duration between arthritis and uveitis onset, young age, male gender and presence of anterior chamber flare (Heiligenhaus et al. 2007; Woreta et al. 2007) .
In another study from the USA by Gregory that examined 327 children (596 affected eyes) with JIA-associated uveitis, 60% of the affected eyes had at least one ocular complication, 40% had a VA ≤20/50 (logMAR ≥0.4) and 24% had a VA ≤20/200 (logMAR ≥1.0) at presentation (Gregory et al. 2013) . Posterior synechiae, active uveitis and prior intraocular surgery were statistically significantly associated with VA ≤20/50 (logMAR ≥0.4) and ≤20/200 (logMAR ≥1.0) thresholds, both at presentation and during follow-up (Gregory et al. 2013) . In our small sample, no significant predictor for severe uveitis could be found.
Ethnicity plays a significant role in various autoimmune diseases such as systemic lupus erythematosus, sarcoidosis and JIA. Children of European descent predominantly develop OA JIA, whereas children of non-European origin (black, native North American and Hispanic) develop PA RF-positive JIA (Saurenmann et al. 2007b; Pelajo et al. 2013) . As JIA subtypes differ in their association with uveitis and race predisposes one to different JIA subtypes, race may influence risk for uveitis. There is a paucity of studies on the impact of race on the risk for uveitis. In 2007, in a cohort in Toronto, the incidence of uveitis in children with JIA was similar in children with European and non-European ancestry (14.4% versus 12.8%), although when compared to the general Toronto population, risk for JIA-associated uveitis was increased in European children and decreased in non-European ancestries (Saurenmann et al. 2007b) . In a recent study from Spain, in a Western urban multiethnic population, childhoodonset uveitis (≤16 years old) was recorded in 7.2% (74/1022) and the main causes of uveitis in children were JIA (27%), pars planitis (16.2%) and toxoplasma retinochoroiditis (14.8%) (Llorenc et al. 2015) . In our study, all but one child (Asian) were Caucasian.
The frequency of complications and the rate of vision loss have been reduced noticeably in recent years when compared to the reported complication rates of 60-90% in chronic uveitis two or Table 5 . Second-line systemic treatment in children with uveitis at onset of uveitis and at last follow-up. three decades ago. In spite of this, JIAassociated uveitis is still associated with a high risk of late sequelae and great risk of loss of VA (Heiligenhaus et al. 2015) . It has been shown previously that initial poor vision was more common when uveitis occurred before or at the time of arthritis onset and when complications had already been detected at the first ophthalmologic examination (Kotaniemi et al. 1999 ). In our study, the only complication that was documented at first visit wastheformationofposteriorsynechiaein eight eyes (14%) of six children (19%). Eighteen children (56.2%) had no secondline systemic treatment at uveitis onset, whereas seven children (21.8%) were without treatment at last follow-up. Children who were on methotrexate (40.6%) continued this treatment either as monotherapy (31.2%) or combinated with TNF-a inhibitor (44%) at last follow-up. Early diagnosis appears to be especially important in order to prevent severe visual loss. Screening guidelines for the early detection of uveitis in children with JIA vary across countries and are based upon the risk factors for uveitis (Edelsten et al. 2002) . The latest recommendations for screening for uveitis in children with JIA were published in 2006 by the American Academy of Pediatrics (Cassidy et al. 2006) . A year later, the German Uveitis in Childhood Study Group suggested a number of changes to these guidelines (Heiligenhaus et al. 2007 ). These recommended intervals for uveitis screening, which are adapted to the uveitis risk of the individual JIA subtypes, are shown in Table 7 . However, there is no mention of the maximum age at which the follow-up screening examinations should be discontinued.
The national screening guidelines in Finland were revised in 2014 according to the intervals suggested by the German Uveitis in Childhood Study Group (Heiligenhaus et al. 2007 ). Screening for uveitis continues until the patient is 16 years of age, and in the case of cessation of disease-modifying antirheumatic drugs such as methotrexate or biological agents, the children are screened every 6 months regardless of JIA subtype. Denmark also presented new national screening guidelines for JIA-associated uveitis in 2015. According to those guidelines, screening for uveitis should continue until the patient is 18 years of age. Both Finnish and Danish guidelines were presented at the Nordic Pediatric Ophthalmology Group/Nordic Strabismological Association (NPOG/NSA) meeting in June 2015 (http://www. npog-nsa.org/npognsa.php).
Concerning Sweden, there has until nowbeennoconsensusregardingnational screening recommendations and the screening intervals for uveitis vary across the country. There is a need for national guidelines and work has recently started among paediatric rheumatologists and paediatric ophthalmologists representing different parts of Sweden. For example, in our clinical practice at the Queen Silvia Children's hospital, children with ANApositive OA under 4 years of age at JIA onset undergo ophthalmological examination every 3 months during the first 5 years and thereafter every 6 months until 12 years of age, based on screening guidelines for uveitis in JIA provided by the British Society for Paediatric and Adolescent Rheumatology (BSPAR) (http://www.bspar.org.uk/clinical-guide lines). According to the present study, only one child developed JIA-associated uveitis between the fourth and fifth years after arthritis onset. Considering this, it may support a modification of our screening guidelines reducing the duration of the three-monthly screening interval from 5 years to the first 4 years for this high risk of JIA subtype, and thereafter screen every 6 months. In general, there is a need foreasilycomprehensiblescreeningguidelines, based on possible risk factors, to apply them in everyday practice in clinics.
In conclusion, most of the epidemiological characteristics found in this study are in accordance with previous studies on Caucasian children with JIA. Our results confirm ANA positivity as the most important predictor of JIA-associated uveitis development. This study -which is not without limitations, including its retrospective nature -may facilitate the optimization of suggested nationwide screening guidelines. Early detection of disease and prompt initiation of treatment are the main aims in management of JIA-associated uveitis. In-depth understanding of the pathogenesis of JIAassociated uveitis could also help to identify novel biomarkers, either genetic or perhaps circulating factors, which would enable targeting of patients in high-risk groups for earlier and more aggressive therapy in order to decrease the odds of poor vision.
